In addition to the Niagen IV and injection rollout, ChromaDex has also significantly fortified its intellectual property portfolio. The U.S. Patent and Trademark Office recently granted ChromaDex a patent for the disodium salt of NMNH (dihydronicotinamide mononucleotide), a key precursor to NAD+. The newly acquired U.S. Patent number 10,000,520 C1, which is co-owned with Queen?s University Belfast (QUB), covers the composition of matter for this novel substance, further cementing ChromaDex?s leadership in the field of NAD+ research and supplementation.